Netherlands· NL-a71950581820

Rasilez 150 mg, filmomhulde tablet

A aliskiren product containing aliskirenhemifumaraat, registered in Netherlands by Noden Pharma DAC. The same ATC class is registered in 13 of our 19 countries.

ATC C09XA02

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about aliskirenhemifumaraatAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Aliskiren is registered in 13 of 19 countries.

Countries holding a registration under ATC C09XA02 (aliskiren), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
9 of them publish a price we can compare per daily dose

Search aliskiren products by name

Aliskiren · ATC C09XA02

13 / 19 countries

Belgiumprice
Czechiaprice
Denmark
Finlandprice
Icelandprice
Ireland
Italyprice
Netherlands
Norwayprice
Polandprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of aliskiren costs, country by country.

Normalised to the WHO defined daily dose (0.15 g), the median price runs from $0.95 in Italy to $3.43 in United States — a ×3.6 gap.

2 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown
US figures are pharmacy acquisition cost (CMS NADAC), not retail

Open the full comparison — free account Drug prices for market access

Aliskiren · price per daily dose (0.15 g)

USD · FX 28 Sept 2026

US United States$3.43 (acquisition cost)
IT Italy$0.95

Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: ALISKIRENHEMIFUMARAAT
Manufacturer: Noden Pharma DAC
Country: Netherlands (NL)
ATC code: C09XA02
ATC class: Aliskiren
Defined daily dose: 0.15 g, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
EU/1/07/405

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

227 interactions on record for aliskiren.

Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check aliskiren against other medicines How interaction checks work

Aliskiren · interactions on record

227 records

1 severe
147 moderate
26 info

Most severe, free to view

CiclosporinL04AD01severe
ClotrimazoleA01AB18moderate
AprepitantA04AD12moderate
RolapitantA04AD14moderate

53 more interactions with mechanism and management, from a commercially licensed source.

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Aliskiren in 9 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All aliskiren products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

Iceland · Rasilez
Liechtenstein · Rasilez
Norway · Rasilez

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/3aa4b8be-010d-4d1d-8160-14266674a590
GET /v1/drugs/3aa4b8be-010d-4d1d-8160-14266674a590?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/rasilez-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Aliskiren",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp73493",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSPOVIDON (E 1202)",
    "HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
    "IJZEROXIDE ROOD  (E 172)",
    "IJZEROXIDE ZWART (E 172)",
    "MACROGOL 4000",
    "MAGNESIUMSTEARAAT (E 470b)",
    "POVIDON K 30 (E 1201)",
    "SILICIUMDIOXIDE (E 551)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "ALISKIRENHEMIFUMARAAT"
  ],
  "leaflet_url": null,
  "authorised_at": "2007/08/22",
  "procedure_number": "EMEA/H/C/000780",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/07/405",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about aliskiren.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console